STEP trial and HIV-1 vaccines inducing T-cell responses

References

• Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol.24, 739–769 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen J. AIDS research. Did Merck’s failed HIV vaccine cause harm? Science318, 1048–1049 (2007).
   PubMed Web of Science ®Google Scholar
• Ledford H. HIV vaccine may raise risk. Nature450, 325 (2007).
   PubMed Web of Science ®Google Scholar
• Aste-Amezaga M, Bett AJ, Wang F et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum. Gene Ther.15, 293–304 (2004).
   PubMed Web of Science ®Google Scholar
• Bauer U, Flunker G, Bruss K et al. Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay. J. Clin. Microbiol.43, 4426–4433 (2005).
   Google Scholar
• Kostense S, Koudstaal W, Sprangers M et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS18, 1213–1216 (2004).
   PubMed Web of Science ®Google Scholar
• Nwanegbo E, Vardas E, Gao W et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol.11, 351–357 (2004).
   PubMedGoogle Scholar
• McCoy K, Tatsis N, Korioth-Schmitz B et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol.81, 6594–6604 (2007).
   PubMed Web of Science ®Google Scholar
• Roberts DM, Nanda A, Havenga MJ et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature441, 239–243 (2006).
   PubMed Web of Science ®Google Scholar
• Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature381, 661–666 (1996).
   PubMed Web of Science ®Google Scholar
• Trkola A, Dragic T, Arthos J et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature384, 184–187 (1996).
   PubMed Web of Science ®Google Scholar
• Cocchi F, DeVico AL, Garzino-Demo A et al. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med.2, 1244–1247 (1996).
   PubMed Web of Science ®Google Scholar
• Staprans SI, Barry AP, Silvestri G et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc. Natl Acad. Sci. USA101, 13026–13031 (2004).
   PubMed Web of Science ®Google Scholar
• Stanley SK, Ostrowski MA, Justement JS et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N. Engl. J. Med.334, 1222–1230 (1996).
   PubMed Web of Science ®Google Scholar
• Denniston GC, Hill G. Male circumcision in HIV prevention. Lancet369, 1598; author reply 1598–1599 (2007).
   Google Scholar
• O’Brien SJ, Gao X, Carrington M. HLA and AIDS: a cautionary tale. Trends Mol. Med.7, 379–381 (2001).
   Google Scholar
• Freeman EE, Weiss HA, Glynn JR et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS20, 73–83 (2006).
   PubMed Web of Science ®Google Scholar
• McMichael AJ. HIV vaccines. Annu. Rev. Immunol.24, 227–255 (2006).
   PubMed Web of Science ®Google Scholar
• Borrow P, Lewicki H, Hahn BE et al. Virus-specific CD8+ CTL activity associated with control of viremia in primary HIV-1 infection. J. Virol.68, 6103–6110 (1994).
   PubMed Web of Science ®Google Scholar
• Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol.68, 4650–4655 (1994).
   PubMed Web of Science ®Google Scholar
• Matano T, Shibata R, Siemon C et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol.72, 164–169. (1998).
   PubMed Web of Science ®Google Scholar
• Jin X, Bauer DE, Tuttleton SE et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med.189, 991–998 (1999).
   PubMed Web of Science ®Google Scholar
• Schmitz JE, Kuroda MJ, Sasseville VG et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science283, 857–860 (1999).
   PubMed Web of Science ®Google Scholar
• Klenerman P, Wu Y, Phillips R. HIV: current opinion in escapology. Curr. Opin. Microbiol.5, 408–413 (2002).
   Google Scholar
• Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science317, 944–947 (2007).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Santra S, Schmitz JE et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science290, 486–492 (2000).
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Wang F, Schleif WA et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing gag. J. Virol.79, 15547–15555 (2005).
   PubMed Web of Science ®Google Scholar
• Kent SJ, Zhao A, Best SJ et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol.72, 10180–10188 (1998).
   PubMed Web of Science ®Google Scholar
• Robinson HL, Montefiori DC, Johnson RP et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med.5, 526–534 (1999).
   PubMed Web of Science ®Google Scholar
• Rowland-Jones SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr. Opin. Immunol.7, 448–455 (1995).
   PubMed Web of Science ®Google Scholar
• Fujiwara M, Takiguchi M. HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages. Blood109, 4832–4838 (2007).
   PubMed Web of Science ®Google Scholar
• Stittelaar KJ, Gruters RA, Schutten M et al. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine20, 2921–2927 (2002).
   PubMed Web of Science ®Google Scholar
• Yang H, Dong T, Turnbull E et al. Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy. J. Immunol.179, 597–606 (2007).
   Google Scholar
• Yang OO, Kalams SA, Trocha A et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolityc and noncytolytic mechanisms. J. Virol.71, 3120–3128 (1997).
   PubMed Web of Science ®Google Scholar
• Alabi AS, Jaffar S, Ariyoshi K et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS17, 1513–1520 (2003).
   Google Scholar
• Hebart H, Daginik S, Stevanovic S et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood99, 3830–3837 (2002).
   PubMed Web of Science ®Google Scholar
• Vine AM, Heaps AG, Kaftantzi L et al. The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J. Immunol.173, 5121–5129 (2004).
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Fitzgerald JC, Grant R et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol.78, 7392–7399 (2004).
   PubMed Web of Science ®Google Scholar
• Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature415, 331–335. (2002).
   PubMed Web of Science ®Google Scholar
• Casimiro D, Dubery S, Tobery T et al. Breadth of the HIV-specific cellular responses to replication – defective adenovirus HIV vaccines in healthy subjects. Presented at: AIDS Vaccine 2006. Amsterdam, The Netherlands, 29 August–1 September 2006.
   Google Scholar
• Baalen CA, Guillon C, Baalen MvM et al. Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur. J. Immunol.32, 2644–2652 (2002).
   Google Scholar
• Kubota R, Soldan SS, Martin R et al. An altered peptide ligand antagonizes antigen-specific T cells of patients with human T lymphotropic virus type I-associated neurological disease. J. Immunol.164, 5192–5198 (2000).
   Google Scholar
• Rowland-Jones SL, Pinheiro S, Kaul R et al. How important is the ‘quality’ of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol. Lett.79, 15–20 (2001).
   Google Scholar
• Zhang D, Shankar P, Xu Z et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood101, 226–235 (2003).
   PubMedGoogle Scholar
• Almeida JR, Price DA, Papagno L et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med.204, 2473–2485 (2007).
   PubMed Web of Science ®Google Scholar
• Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood107, 4781–4789 (2006).
   PubMed Web of Science ®Google Scholar
• Appay V, Dunbar PR, Callan M et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med.8, 379–385 (2002).
   PubMed Web of Science ®Google Scholar
• Harari A, Vallelian F, Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur. J. Immunol.34, 3525–3533 (2004).
   PubMed Web of Science ®Google Scholar
• Harari A, Zimmerli SC, Pantaleo G. Cytomegalovirus (CMV)-specific cellular immune responses. Hum. Immunol.65, 500–506 (2004).
   PubMedGoogle Scholar
• Lin SW, Hensley SE, Tatsis N et al. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J. Clin. Invest.117, 3958–3970 (2007).
   PubMed Web of Science ®Google Scholar
• Leifer CA, Verthelyi D, Klinman DM. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J. Immunother.26, 313–319 (2003).
   PubMedGoogle Scholar
• Schulz O, Diebold SS, Chen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature433, 887–892 (2005).
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol. Rev.211, 320–337 (2006).
   PubMed Web of Science ®Google Scholar
• Estcourt MJ, Letourneau S, McMichael AJ et al. Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur. J. Immunol.35, 2532–2540 (2005).
   PubMed Web of Science ®Google Scholar
• Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat. Med.11, S54–S62 (2005).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell124, 849–863 (2006).
   PubMed Web of Science ®Google Scholar
• Querec T, Bennouna S, Alkan S et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med.203, 413–424 (2006).
   PubMed Web of Science ®Google Scholar
• Goonetilleke N, Moore S, Dally L et al. Prime–boost vaccination with recombinant DNA and MVA expressing HIV-1 clade A gag and immunodominant CTL epitopes induces multi-functional HIV-1-specific T cells in healthy subjects. J. Virol.80, 4717–4728 (2006).
   PubMed Web of Science ®Google Scholar
• Harari A, Bart PA, Stohr W et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med.205, 63–77 (2008).
   PubMed Web of Science ®Google Scholar
• Lemckert AA, Sumida SM, Holterman L et al. Immunogenicity of heterologous prime–boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol.79, 9694–9701 (2005).
   PubMed Web of Science ®Google Scholar
• Tatsis N, Lin SW, Harris-McCoy K et al. Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. Virology367, 156–167 (2007).
   PubMed Web of Science ®Google Scholar
• McDermott AB, O’Connor DH, Fuenger S et al. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J. Virol.79, 15556–15566 (2005).
   PubMed Web of Science ®Google Scholar
• Wilson NA, Reed J, Napoe GS et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol.80, 5875–5885 (2006).
   PubMed Web of Science ®Google Scholar
• Letourneau S, Im E-J, Mashishi T et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE2(10), e984 (2007).
   PubMed Web of Science ®Google Scholar
• Gaschen B, Taylor J, Yusim K et al. Diversity considerations in HIV-1 vaccine selection. Science296, 2354–2360 (2002).
   PubMed Web of Science ®Google Scholar
• Fischer W, Perkins S, Theiler J et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med.13, 100–106 (2007).
   PubMed Web of Science ®Google Scholar
• Nickle DC, Rolland M, Jensen MA et al. Coping with viral diversity in HIV vaccine design. PLoS Comput. Biol.3, e75 (2007).
   PubMedGoogle Scholar
• Rolland M, Jensen MA, Nickle DC et al. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J. Virol.81, 8507–8514 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrari G, Kostyu DD, Cox J et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res. Hum. Retroviruses16, 1433–1443 (2000).
   Google Scholar
• Wilson CC, McKinney D, Anders M et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J. Immunol.171, 5611–5623 (2003).
   PubMed Web of Science ®Google Scholar
• Catanzaro AT, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect. Dis.194, 1638–1649 (2006).
   PubMed Web of Science ®Google Scholar
• Catanzaro AT, Roederer M, Koup RA et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine25, 4085–4092 (2007).
   PubMed Web of Science ®Google Scholar
• Korber B, Gaschen B, Yusim K et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull.58, 19–42 (2001).
   PubMed Web of Science ®Google Scholar
• Honeyborne I, Prendergast A, Pereyra F et al. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J. Virol.81, 3667–3672 (2007).
   PubMed Web of Science ®Google Scholar
• Kiepiela P, Ngumbela K, Thobakgale C et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med.13, 46–53 (2007).
   PubMed Web of Science ®Google Scholar
• Rolland M, Heckerman D, Deng W et al. Broad and gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE3, e1424 (2008).
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis.191, 654–665 (2005).
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Peterson ML, Follmann D et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a Phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis.191, 666–677 (2005).
   PubMed Web of Science ®Google Scholar
• Mills E, Siegfried N. Cautious optimism for new HIV/AIDS prevention strategies. Lancet368, 1236 (2006).
   Google Scholar
• Excler JL, Rida W, Priddy F et al. A strategy for accelerating the development of preventive AIDS vaccines. AIDS21, 2259–2263 (2007).
   PubMed Web of Science ®Google Scholar
• Steinbrook R. One step forward, two steps back – will there ever be an AIDS vaccine? N. Engl. J. Med.357, 2653–2655 (2007).
   PubMed Web of Science ®Google Scholar